Fatal Adverse Events Associated With Immune Checkpoint Inhibitors in Non–small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Background: Immune checkpoint inhibitors (ICIs) have previously been reported to have a promising potential in terms of the improvement of outcomes in non–small cell lung cancer (NSCLC). Fatal adverse events (FAEs) of ICIs are relatively uncommon, and the incidence and risk in NSCLC remain unclear....

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xiaolin, Zhang, Xiaomei, Yao, Ting, Zhang, Ye, Zhang, Yanxia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917063/
https://www.ncbi.nlm.nih.gov/pubmed/33659263
http://dx.doi.org/10.3389/fmed.2021.627089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7917063/
https://www.ncbi.nlm.nih.gov/pubmed/33659263
http://dx.doi.org/10.3389/fmed.2021.627089

Ejemplares similares